Nasdaq:US$19.17 (-0.48) | HKEX:HK$31.00 (-0.50) | AIM:£3.35 (+0.1)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors